https://orcid.org/0000-0001-9040-1681
References
- Akazawa T, Uchida Y, Miyauchi E, et al. (2018). High expression of UGT1A1/1A6 in monkey small intestine: comparison of protein expression levels of cytochromes P450, UDP-glucuronosyltransferases, and transporters in small intestine of cynomolgus monkey and human. Mol Pharm 15:127–40.
- Ando Y, Saka H, Ando M, et al. (2000). Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60:6921–6.
- Guillemette C. (2003). Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics J 3:136–58.
- Guillemette C, Levesque E, Harvey M, et al. (2010). UGT genomic diversity: beyond gene duplication. Drug Metab Rev 42:24–44.
- Innocenti F, Vokes EE, Ratain MJ. (2006). Irinogenetics: what is the right star? J Clin Oncol 24:2221–4.
- Korprasertthaworn P, Rowland A, Lewis BC, et al. (2012). Effects of amino acid substitutions at positions 33 and 37 on UDP-glucuronosyltransferase 1A9 (UGT1A9) activity and substrate selectivity. Biochem Pharmacol 84:1511–21.
- Minami H, Sai K, Saeki M, et al. (2007). Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genomics 17:497–504.
- Ritter JK. (2000). Roles of glucuronidation and UDP-glucuronosyltransferases in xenobiotic bioactivation reactions. Chem Biol Interact 129:171–93.
- Tukey RH, Strassburg CP. (2000). Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40:581–616.
- Uno Y, Murayama N, Kato M, et al. (2018a). Genetic variants of glutathione S-transferase GSTT1 and GSTT2 in cynomolgus macaques: identification of GSTT substrates and functionally relevant alleles. Chem Res Toxicol 31:1086–91.
- Uno Y, Murayama N, Tamura K, Yamazaki H. (2019a). Functionally relevant genetic variants of glutathione S-transferase GSTM5 in cynomolgus and rhesus macaques. Xenobiotica 49:995–1000.
- Uno Y, Shimizu M, Yoda H, et al. (2019b). Non-synonymous genetic variants of flavin-containing monooxygenase 3 (FMO3) in cynomolgus macaques. Drug Metab Pharmacokinet 34:104–7.
- Uno Y, Takahira R, Murayama N, et al. (2018b). Molecular and functional characterization of UDP-glucuronosyltransferase 1A in cynomolgus macaques. Biochem Pharmacol 155:172–81.
- Uno Y, Takahira R, Murayama N, et al. (2019c). Functional and molecular characterization of UDP-glucuronosyltransferase 2 family in cynomolgus macaques. Biochem Pharmacol 163:335–44.
- Uno Y, Uehara S, Inoue T, et al. (2020). Molecular characterization of functional UDP-glucuronosyltransferases 1A and 2B in common marmosets. Biochem Pharmacol 172:113748
- Uno Y, Uehara S, Murayama N, Yamazaki H. (2018c). Cytochrome P450 1A1, 2C9, 2C19, and 3A4 polymorphisms account for interindividual variability of toxicological drug metabolism in cynomolgus macaques. Chem Res Toxicol 31:1373–81.
- Uno Y, Uehara S, Yamazaki H. (2018d). Genetic polymorphisms of drug-metabolizing cytochrome P450 enzymes in cynomolgus and rhesus monkeys and common marmosets in preclinical studies for humans. Biochem Pharmacol 153:184–95.
- Wang H, Yuan L, Zeng S. (2011). Characterizing the effect of UDP-glucuronosyltransferase (UGT) 2B7 and UGT1A9 genetic polymorphisms on enantioselective glucuronidation of flurbiprofen. Biochem Pharmacol 82:1757–63.
- Yamamoto K, Mukai M, Nagaoka K, et al. (2014). Functional characterization of cynomolgus monkey UDP-glucuronosyltransferase 1A9. Eur J Drug Metab Pharmacokinet 39:195–202.